Study shows most doctors endorsing drugs on X are paid to do so
A new study finding that most physicians who promote specific drugs or devices on X (Twitter) receive industry payments has reignited concerns about conflicts of interest in medicine. Commenters examine U.S. transparency mechanisms like the Open Payments database, argue over whether disclosure requirements are adequate, and debate if paid endorsements should affect a doctor’s license. The thread widens into a critique of pharmaceutical influence on prescribing, direct-to-consumer drug advertising, and public reliance on medical interventions versus lifestyle and environmental factors in health.
Access to the Study and Data Sources
- Commenters share direct links to the JAMA paper and to a ResearchGate copy, noting the article does not list the specific 28 physicians analyzed.
- The U.S. Open Payments database is highlighted as a key tool for checking financial ties between physicians and industry.
- Example searches show some prominent media doctors receiving six‑figure consulting payments, while others have only small “food and beverage” entries.
Magnitude and Nature of Payments
- Related coverage cites $12.1B in payments to U.S. doctors over 2013–2022.
- Some argue the average (~$12k/doctor/year) sounds modest; others say that much is effectively “a month’s salary,” and thus a powerful incentive.
- Clarification that free drug samples are not included; reported items range from brief paid consulting to high‑paid speaking and advisory roles.
Transparency, Disclosure, and Regulation
- Debate over whether U.S. rules adequately mirror social‑media advertising standards requiring clear, in‑context sponsorship disclosure.
- Some see Open Payments as sufficient transparency; others call it a “pretend solution” because most patients don’t know it exists or won’t check it.
- There is disagreement about what is currently illegal: some assert doctors must disclose conflicts and that prescribing under undisclosed influence is unlawful; others say enforcement is weak or unclear.
- Comparisons are made to stricter advertising rules in other countries (e.g., no direct‑to‑consumer Rx ads).
Ethical Concerns and Patient Trust
- Many argue that being paid to endorse drugs is inherently in tension with a physician’s duty of loyalty to patients, especially given information asymmetry and patient vulnerability.
- Some call for revoking licenses for undisclosed endorsements and criminal penalties for company “bribery.”
- Others accept paid roles if conflicts are clearly disclosed, both publicly and to individual patients.
Influence on Prescribing and Public Messaging
- Cited evidence and discussion agree that marketing does influence physician behavior, even when framed as “education” about new approvals.
- Direct‑to‑consumer ads are criticized for prompting patients to demand specific drugs, which some fear doctors may prescribe rather than re‑fight lifestyle battles.
- A personal anecdote describes a doctor’s office saturated with a single drug’s branding and strong pressure to stay on that drug despite serious side effects, interpreted as evidence of distorted incentives.
Broader Skepticism and Health Culture
- Several comments express broad distrust of the pharmaceutical–medical complex, calling the system “corrupt” and focused on wealth extraction.
- Others distinguish between skepticism of companies and trust in specific treatments (e.g., vaccines), noting that corruption in promotion does not automatically mean a drug is ineffective.
- A side discussion explores how culture, urban design, and diet interact with heavy reliance on pharmacologic solutions, especially around obesity, with disagreement over whether lifestyle or drugs should be emphasized.